Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic dysfunction-associated steatohepatitis (MASH)

Metabolic liver disease might not get as much attention as heart disease or diabetes, but it affects around one in four people worldwide. Once called non-alcoholic fatty liver disease, this condition now goes by the name metabolic dysfunction-associated steatotic liver disease,